However, two clinically validated and FDA approved lung cancer predictive biomarkers (EGFR and ALK translocations) occur in only about 20% of lung adenocarcinomas and acquired resistance develops to first generation drugs (Cagle et al. 2016). This evidence concerns the gene EGFR and lung adenocarcinoma.